Paraneoplastic Syndromes

Slide 1 · Paraneoplastic Syndromes

Systemic effects of cancer beyond direct invasion and metastasis

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Learning objectives

Define a paraneoplastic syndrome and distinguish it from direct tumor effects.

Relate ectopic secretions, immune responses, and procoagulant products to clinical syndromes.

Recognize characteristic cancer–syndrome associations across organ systems.

Use clinicopathologic clues without equating association with definitive diagnosis.

CLINICOPATHOLOGIC POINT

Organize every syndrome by mechanism, phenotype, and associated tumor.

Slide 3 · The defining concept

A cancer-associated clinical disorder not readily explained by tumor location or native endocrine function.

A tumor can produce systemic effects at sites remote from the mass.

The syndrome may be recognized before the underlying malignancy.

The mechanism may be secretory, immune, or prothrombotic.

Slide 4 · What paraneoplastic does—and does not—mean

Within the definition

Different mechanism

Remote functional consequences of tumor-derived mediators

Cross-reactive immune injury to normal tissues

Systemic coagulation activation by tumor products

Direct compression or infiltration by a mass

Metastatic organ destruction or osteolysis

Ordinary secretion from a tumor’s native endocrine lineage

The clinical phenotype alone cannot establish which mechanism is operating.

Slide 5 · Why recognition matters

Early clue

May be the initial signal of an otherwise occult cancer.

Serious disease

Can cause major morbidity and sometimes death.

Diagnostic confusion

Can imitate metastasis and distort treatment decisions.

Slide 6 · Clinical presentation may precede cancer detection

Paraneoplastic manifestation

Suspicion of occult neoplasm

Search for underlying malignancy

Clinicopathologic attribution

The order of presentation may be reversed: Systemic manifestation first, cancer diagnosis later.

Finding a characteristic syndrome prompts investigation; It does not prove a particular tumor.

Slide 7 · Mechanisms: A unifying overview

Cancer

Ectopic secretion

Hormones / hormone-like proteins

Immune response

Cross-reactive injury

Tumor products

Clot activation or immune complexes

Slide 8 · Major clinical categories

System

Representative syndromes

Endocrine / metabolic

Cushing syndrome; SIADH; Hypercalcemia; Hypoglycemia; Polycythemia; Osteomalacia

Neuromuscular

Peripheral / CNS dysfunction; Polymyopathy; Myasthenic syndrome

Cutaneous / skeletal

Acanthosis nigricans; Dermatomyositis; Hypertrophic osteoarthropathy

Vascular / other

Trousseau phenomenon; DIC; NBTE; Red cell aplasia; Nephrotic syndrome

Slide 9 · Ectopic hormone production

Nonendocrine cancer

Abnormal secretory activity

Circulating hormone-like factor

Distant target-organ effect

The causal secretion is ectopic because the cancer is not of the corresponding endocrine origin.

Interpret endocrine manifestations in relation to the tumor’s tissue lineage.

Slide 10 · Paraneoplastic Cushing syndrome

Corticotropin (ACTH) or ACTH-like peptides are produced by a nonpituitary neoplasm.

The source is commonly carcinoma of lung, especially small-cell carcinoma.

The syndrome represents an ectopic source of a normally pituitary hormone.

CLINICOPATHOLOGIC POINT

The text identifies Cushing syndrome as the most common paraneoplastic endocrinopathy.

Slide 11 · ACTH derives from a larger precursor

Tumor cell

Pro-opiomelanocortin (POMC)

Corticotropin (ACTH)

Cushing phenotype

POMC is the large precursor molecule from which corticotropin is derived.

Elevated circulating POMC and ACTH in lung-cancer–associated Cushing syndrome.

Slide 12 · POMC helps distinguish source patterns

Ectopic ACTH in lung carcinoma

Pituitary ACTH excess

Circulating ACTH elevated

Circulating precursor POMC elevated

Nonpituitary cancer is the secretory source

Corticotropin excess originates in the pituitary

POMC is not found in serum in the source comparison

Anatomic / secretory origin is different

Source-reported distinction; Not a standalone modern diagnostic algorithm.

Slide 13 · Tumors linked to ectopic ACTH

Associated tumor table

Clinical association

Small-cell carcinoma of lung

Cushing syndrome

Pancreatic carcinoma

Cushing syndrome

Neural tumors

Cushing syndrome

Slide 14 · SIADH as a tumor-associated endocrinopathy

The syndrome of inappropriate antidiuretic hormone secretion is included among ectopic endocrine effects.

Small-cell carcinoma of the lung is a principal tumor association.

Intracranial neoplasms are also listed as associated lesions.

CLINICOPATHOLOGIC POINT

The source table implicates antidiuretic hormone or atrial natriuretic hormones.

Slide 15 · Different secretory outputs, different syndromes

ACTH-related phenotype

Antidiuretic hormone–related phenotype

Ectopic corticotropin or related peptides

Cushing syndrome

Small-cell lung carcinoma is prominent

Inappropriate water-regulating hormone activity

SIADH clinical syndrome

Small-cell lung and intracranial tumors listed

Both are endocrine presentations; The secreted mediator determines the target physiology.

Slide 16 · Cancer-associated hypercalcemia: Two processes

Local skeletal disease

Humoral effect

Osteolysis from primary bone cancer

Bone destruction by metastases

Not classified as paraneoplastic in this definition

Extraosseous tumor releases calcemic substances

Systemic calcium regulation is altered

This pathway is paraneoplastic

Always separate osteolytic disease from humoral hypercalcemia.

Slide 17 · The humoral hypercalcemia pathway

Extraosseous malignancy

Circulating calcemic mediator

Bone and kidney responses

Elevated serum calcium

The systemic mediator pathway does not require tumor infiltration of bone.

Parathyroid hormone–related protein (PTHrP) is the major factor discussed.

Slide 18 · PTHrP resembles PTH in selected activities

Parathyroid hormone–related protein (PTHrP) shares partial structural homology with PTH.

Both ligands bind the same G protein–coupled receptor.

Their biologic actions overlap, but are not identical.

CLINICOPATHOLOGIC POINT

Shared receptor does not mean every physiologic effect is equivalent.

Slide 19 · A common PTH / PTHrP receptor

PTH or PTHrP

Shared PTH / PTHrP receptor

Target-tissue signaling

Mineral balance effects

Receptor identity explains why ectopic PTHrP can imitate selected effects of PTH.

The tumor supplies the ligand; Normal tissues supply the receptors.

Slide 20 · How PTHrP raises circulating calcium

PTHrP

Bone

Increased resorption

Kidney: Calcium

Increased renal calcium uptake

Kidney: Phosphate

Inhibited phosphate transport

Slide 21 · PTHrP is not exclusive to cancer

Small quantities are normally produced by several tissues.

Normal epithelial cells, including keratinocytes, can produce PTHrP.

This distribution provides a plausible link to PTHrP-producing squamous cell carcinoma.

CLINICOPATHOLOGIC POINT

Normal expression and tumor-associated excess are distinct biological contexts.

Slide 22 · Tumors implicated in humoral hypercalcemia

Cancer association

Clinicopathologic distinction

Squamous cell carcinoma of lung

PTHrP release is a characteristic mechanism

Breast carcinoma

Humoral effect may coexist with osteolytic metastases

Renal and ovarian carcinomas

Both associated with humoral calcium disturbances

Adult T-cell leukemia / lymphoma

Hematolymphoid tumor associated with hypercalcemia

Slide 23 · Additional humoral mediators

Robbins also implicates IL-1, transforming growth factor-α, and tumor necrosis factor.

Dihydroxyvitamin D is another factor named in the narrative.

Hypercalcemia in malignancy is therefore not always reducible to a single molecular factor.

CLINICOPATHOLOGIC POINT

The mediator list describes plausible causes—not a ranking of tests or treatment targets.

Slide 24 · Mixed mechanisms in breast cancer

Breast carcinoma

Humoral factor production

Coexisting bone metastases

Amplified hypercalcemia

Bone metastases may exacerbate a paraneoplastic humoral calcium disturbance.

Do not label osteolysis itself as paraneoplastic merely because PTHrP is also involved.

Slide 25 · Hypercalcemia: Mechanism-based reasoning

CLINICAL PROBLEM

A patient with carcinoma has elevated calcium and osseous metastatic disease. Does “hypercalcemia” alone identify a paraneoplastic syndrome?

INTERPRETATION

No. Osteolysis is a direct tumor effect; A separate circulating calcemic factor is the paraneoplastic pathway.

A patient may have both pathways simultaneously, particularly with breast cancer.

Slide 26 · Paraneoplastic hypoglycemia

The source table links ovarian carcinoma and fibrosarcoma with hypoglycemia.

Insulin or insulin-like substances are the proposed mediators.

The mechanism is classified with ectopic tumor-derived metabolic effects.

CLINICOPATHOLOGIC POINT

The extracted chapter does not specify a confirmatory laboratory protocol.

Slide 27 · Tumor-associated polycythemia

Renal / liver / other tumor

Erythropoietin release

Stimulation of red-cell production

Polycythemia

Associated tumors in the table: Renal carcinoma, hepatocellular carcinoma, and cerebellar hemangioma.

The secretory product—not tumor bulk—explains the hematologic phenotype.

Slide 28 · FGF-23 and tumor-associated osteomalacia

Phosphaturic mesenchymal tumor

Fibroblast growth factor 23

Phosphate-handling disturbance

Osteomalacia

FGF-23 as the mediator of this distinctive syndrome.

This is a bone disorder arising from a circulating tumor product, not skeletal invasion.

Slide 29 · Endocrine syndrome-to-mediator map

Clinical syndrome

Proposed mediator

Illustrative tumor

Cushing syndrome

ACTH / ACTH-like

Small-cell lung carcinoma

SIADH

ADH / natriuretic hormones

Small-cell lung carcinoma

Hypercalcemia

PTHrP and other factors

Squamous lung carcinoma

Polycythemia

Erythropoietin

Renal carcinoma

Osteomalacia

FGF-23

Phosphaturic mesenchymal tumor

Slide 30 · One cancer can produce different syndromes

CLINICAL PROBLEM

Small-cell lung carcinoma is associated with Cushing syndrome and SIADH in the same source table. What determines the syndrome?

INTERPRETATION

The tumor-associated secretory product and its target-organ effects—not simply the primary tumor site.

The same histologic cancer category may be linked to different systemic presentations.

Slide 31 · Neuromyopathic syndrome spectrum

Anatomic / functional pattern

Examples

Peripheral nervous system

Peripheral neuropathies

Central nervous system

Encephalitis; Cortical cerebellar degeneration

Skeletal muscle

Polymyopathy resembling polymyositis

Neuromuscular transmission

Myasthenic syndrome resembling myasthenia gravis

Slide 32 · Immune cross-reactivity: Proposed sequence

Tumor expresses neural antigen

Host immune recognition

Cross-reactive immune response

Injury to normal neural tissue

Tumor expression of antigens normally restricted to the neuromuscular system is proposed as an initiating event.

The text treats this model as plausible; Mechanisms remain incompletely understood.

Slide 33 · Cellular and humoral immune effectors

T-cell–associated mechanisms

Antibody-associated mechanisms

Immune responses frequently involve T cells

Tissue injury may reflect immune-cell attack

The cross-reactive target is host tissue

Cross-reactive neuronal antibodies occur in some syndromes

Antibodies may recognize neuronal antigens

Detection is not described as universal

Avoid assuming one antibody-mediated mechanism for all neurologic syndromes.

Slide 34 · Peripheral neuropathy as a remote effect

Peripheral neuropathies are among the neuromyopathic manifestations.

A remote immune process can affect nerves without local tumor invasion.

Direct nerve compression and metastatic involvement remain distinct mechanisms to exclude.

CLINICOPATHOLOGIC POINT

Neuropathy is a presentation category, not proof of a particular cancer.

Slide 35 · Encephalitis in cancer-associated immunity

Encephalitis appears in the source list of paraneoplastic neurologic syndromes.

The immunologic model explains CNS injury in the absence of direct tumor spread.

Anatomic localization of dysfunction is separate from localization of the malignancy.

CLINICOPATHOLOGIC POINT

The source excerpt does not specify named encephalitic antibody subtypes.

Slide 36 · Paraneoplastic cerebellar degeneration

Cancer-associated immune response

Cross-reactive CNS target

Cerebellar tissue dysfunction

Cerebellar clinical syndrome

Cortical cerebellar degeneration among the neuromyopathic forms.

The flowchart is a conceptual interpretation, not a microscopic description.

Slide 37 · A polymyopathy resembling polymyositis

Cancer-associated muscular dysfunction may resemble polymyositis.

The source groups this with probable immune-mediated neuromyopathic syndromes.

A muscle-centered phenotype can be paraneoplastic despite an extra-muscular primary tumor.

CLINICOPATHOLOGIC POINT

Similar clinical patterns do not establish identical etiology.

Slide 38 · Myasthenic syndrome: Phenotype versus cause

Observed resemblance

Paraneoplastic attribution

Myasthenic syndrome resembles myasthenia gravis

Neuromuscular dysfunction is prominent

The clinical pattern directs evaluation

A neoplasm-associated immunologic mechanism is proposed

Not explained merely by tumor mass

Bronchogenic and thymic tumors in its myasthenia row

The source does not provide subtype-specific electrophysiologic criteria.

Slide 39 · Direct neurologic injury versus paraneoplastic

Direct or metastatic

Paraneoplastic / immune

Mass effect in neural tissue

Structural infiltration or compression

Neurologic localization may match a tumor deposit

Immune response directed against host antigens

Remote organ dysfunction

A primary cancer may be anatomically distant

The distinction changes interpretation of neurologic findings in oncology.

Slide 40 · Reasoning exercise: A neurologic clue

CLINICAL PROBLEM

A patient develops a progressive neurologic syndrome and later is found to have breast carcinoma. Is the neurologic syndrome necessarily metastatic?

INTERPRETATION

No. Breast carcinoma is linked to neurologic paraneoplastic disorders; Determine the mechanism rather than assuming metastasis.

The original source specifically warns that paraneoplastic syndromes can mimic spread of cancer.

Slide 41 · Cutaneous manifestations

Manifestation

Tumor associations in source

Mechanism stated

Acanthosis nigricans

Gastric, lung, uterine carcinoma

Immune / EGF-associated

Dermatomyositis

Bronchogenic and breast carcinoma

Immunologic

Leser–Trélat sign

May accompany acanthosis nigricans

Association / temporal clue

Slide 42 · Acanthosis nigricans: Recognizable morphology

Gray-black, thickened, hyperkeratotic plaques with a velvety surface.

The morphology is cutaneous, although the associated cancer may be visceral.

Texture and color are part of the clinical description.

The source notes gastric carcinoma particularly often among associated cancers.

Slide 43 · Acanthosis nigricans is not always malignant

Nonmalignant setting

Paraneoplastic setting

Can occur as a genetically determined condition

May be seen in juveniles or adults

Phenotype alone is insufficient

Described with several carcinomas

The source emphasizes adult presentations, especially after age 40

May arise before cancer detection

An approximate cancer association in about half of the cases considered; Context matters.

Slide 44 · Leser–Trélat sign

Describes abrupt appearance of multiple seborrheic keratoses.

Can occur alongside acanthosis nigricans.

The skin eruption may precede recognition of an underlying cancer.

CLINICOPATHOLOGIC POINT

A temporal association is a clinical clue; It is not tumor histology.

Slide 45 · Dermatomyositis as a paraneoplastic clue

Dermatomyositis is included as an immunologic dermatologic manifestation.

Bronchogenic and breast carcinomas are listed associations.

In this context, the cutaneous and muscle phenotype requires separation from direct cancer effects.

CLINICOPATHOLOGIC POINT

The table does not specify a particular autoantibody or diagnostic sensitivity.

Slide 46 · Cutaneous findings can reverse the sequence of diagnosis

New skin manifestations

Clinical pattern recognized

Underlying malignancy considered

Tumor subsequently identified

That acanthosis-associated changes may appear before cancer is discovered.

Timing is clinically informative but does not itself prove causality.

Slide 47 · Hypertrophic osteoarthropathy: Defining triad

Periostosis

New bone deposition along distal long bones and small tubular bones.

Arthritis

Inflammation or symptoms at adjacent joints.

Clubbing

Enlargement / characteristic change of distal digits.

Slide 48 · Where the bone change occurs

Schematic

New bone on the outer periosteal surface

Periosteal new bone formation

Distal long bones

Metatarsals, metacarpals and proximal phalanges

Native schematic of bone surface apposition; Not a radiograph or histologic specimen.

Slide 49 · Periosteal bone change and joint symptoms

Hypertrophic osteoarthropathy

Periosteal new bone

Adjacent-joint involvement

Osseous / articular syndrome

The skeletal pattern links distal periosteal deposition with arthritis of adjacent joints.

Bone involvement here reflects systemic change, not necessarily metastatic deposits.

Slide 50 · Clubbing is not cancer-specific

Neoplastic association

Noncancer associations

Bronchogenic carcinoma

Thymic neoplasms

May occur within hypertrophic osteoarthropathy

Diffuse pulmonary and liver disease

Congenital cyanotic heart disease

Ulcerative colitis and other disorders

Clubbing can be present without full osteoarthropathy.

Slide 51 · Osteoarthropathy: Association and uncertainty

Hypertrophic osteoarthropathy in 1%–10% of lung carcinoma cases.

The syndrome is less often associated with other cancers.

Its cause is described as unknown in this source.

CLINICOPATHOLOGIC POINT

Do not assign an unverified molecular mechanism to this classic morphologic triad.

Slide 52 · Vascular manifestations: Three different lesions

Disorder

Primary pathologic process

Trousseau phenomenon

Migratory venous thrombophlebitis

Disseminated intravascular coagulation

Generalized intravascular activation of clotting

Nonbacterial thrombotic endocarditis

Bland fibrinous vegetations on valve leaflets

Slide 53 · Trousseau phenomenon

Migratory thrombophlebitis is associated with deep-seated cancers.

Pancreatic carcinoma is a prominent source association.

Lung carcinoma and other cancers are also implicated.

CLINICOPATHOLOGIC POINT

The syndrome is a manifestation of cancer-associated hypercoagulability.

Slide 54 · Tumor products can activate clotting

Malignant tumor

Released products, including mucins

Activation of clotting pathways

Thrombosis / systemic sequelae

Mucins are an example listed in the source—not a universal mechanism.

The thrombotic clinical syndrome is remote from the tumor’s anatomic site.

Slide 55 · Disseminated intravascular coagulation

Cancer-associated products

Widespread clotting activation

Disseminated intravascular coagulation

Hematologic / vascular consequences

The excerpt places DIC among malignant vascular syndromes.

The source table associates it particularly with selected cancers.

Slide 56 · Malignancies prominent in DIC

Neoplasm

Syndrome association

Acute promyelocytic leukemia

Disseminated intravascular coagulation

Prostatic adenocarcinoma

Disseminated intravascular coagulation

Slide 57 · Nonbacterial thrombotic endocarditis

Schematic

Valve leaflet (schematic segment)

Bland fibrinous deposits

Bland, small, noninfective fibrinous vegetations form on cardiac valve leaflets, often on left-sided valves.

Potential source of emboli

Slide 58 · Why valve vegetations matter

Advanced cancer

Hypercoagulability

Bland valve vegetation

Potential systemic embolism

The source highlights advanced mucin-secreting adenocarcinomas.

Embolization adds a distinct complication beyond the underlying cancer.

Slide 59 · Distinguishing three prothrombotic patterns

Syndrome

Main site / pattern

Clinical interpretation

Trousseau

Migrating venous thrombophlebitis

Cancer-linked venous thrombosis

DIC

Diffuse intravascular coagulation

Systemic clotting activation

NBTE

Cardiac valvular fibrin deposits

Potential source of emboli

Slide 60 · Paraneoplastic red cell aplasia

Red cell aplasia is included among hematologic paraneoplastic syndromes.

Thymic neoplasms and large granular lymphocytic leukemia are listed associations.

An immunologic mechanism is proposed.

CLINICOPATHOLOGIC POINT

Distinct from erythropoietin-associated polycythemia: Opposite hematologic phenotypes.

Slide 61 · Nephrotic syndrome in patients with cancer

Neoplasm

Tumor antigens / immune complexes

Renal immune involvement

Nephrotic syndrome

Nephrotic syndrome in association with various cancers.

The table invokes tumor antigens and immune complexes as possible mediators.

Slide 62 · The same organ system may show opposing outcomes

Red-cell excess

Red-cell failure

Polycythemia

Erythropoietin as secreted mediator

Renal, hepatic, cerebellar tumors listed

Pure red cell aplasia

Presumed immunologic process

Thymic neoplasms / large granular lymphocytic leukemia

Mechanism is more informative than the label “hematologic paraneoplastic.”

Slide 63 · Tumor–syndrome associations are patterns, not proofs

The Robbins table presents major forms of associated cancer, not exhaustive lists.

One syndrome may accompany several unrelated tumors.

One tumor type may be linked to several different paraneoplastic phenotypes.

Attribution requires excluding direct effects and competing causes.

CLINICOPATHOLOGIC POINT

Use the association to guide hypotheses—not to conclude a specific diagnosis from one sign.

Slide 64 · Integrated recognition framework

Identify clinical phenotype

Exclude direct tumor effects

Assess proposed mediator class

Evaluate associated malignancy

Classify: Secretory, immune-mediated, skeletal/dermatologic, or thrombotic.

Then match with tumor association and the temporal clinical context.

Slide 65 · Application: Endocrine phenotype

CLINICAL PROBLEM

A lung tumor is associated with elevated ACTH and POMC in the circulation. Which paraneoplastic mechanism best fits?

INTERPRETATION

Ectopic ACTH-related Cushing syndrome, classically associated with small-cell carcinoma.

The precursor relationship and lung-cancer association are both explicit.

Slide 66 · Application: Distal bone and joint findings

CLINICAL PROBLEM

A person with lung cancer develops finger clubbing, distal periosteal new bone formation, and adjacent-joint arthritis. What syndrome links the findings?

INTERPRETATION

Hypertrophic osteoarthropathy.

The three findings form its defining clinicopathologic triad. The exact cause remains unknown in the excerpt.

Slide 67 · Application: Migratory venous thrombosis

CLINICAL PROBLEM

A patient with a deep-seated pancreatic carcinoma experiences migratory thrombophlebitis. What paraneoplastic pattern is illustrated?

INTERPRETATION

Trousseau phenomenon, a cancer-associated hypercoagulable syndrome.

The source connects tumor products such as mucins with activation of clotting.

Slide 68 · Application: A CNS syndrome before tumor discovery

CLINICAL PROBLEM

A neurologic presentation appears before any malignancy is known. How might this still be cancer-related?

INTERPRETATION

An occult tumor could trigger a cross-reactive immune response to neural antigens.

The manifestation may precede cancer detection and should not automatically be interpreted as metastatic disease.

Slide 69 · Synthesis: Organize by causal mechanism

Dominant mechanism

Illustrative presentation

Ectopic secretion

Cushing syndrome; Hypercalcemia; Polycythemia; Osteomalacia

Immune injury

Neuromyopathic syndromes; Dermatomyositis; Red cell aplasia

Procoagulant products

Trousseau phenomenon; DIC; NBTE

Other / less certain

Hypertrophic osteoarthropathy; Acanthosis nigricans

Slide 70 · Four final clinicopathologic principles

Paraneoplastic manifestations are not synonymous with metastatic disease.

A circulating mediator or immune response may explain a distant organ phenotype.

Specific combinations of syndromes and tumor types provide diagnostic clues.

The mechanism and degree of causal certainty must be stated explicitly.

CLINICOPATHOLOGIC POINT

For any remote cancer-associated sign, determine whether a secretory, immune, or procoagulant process is supported.